Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The long wait for long-acting HIV prevention and treatment formulations.
Venter WDF, Gandhi M, Sokhela S, Sikwese K, Bygrave H, Gama LD, Mphothulo N, Jamieson L, Siedner MJ, Pozniak AL, Rojo P, Baptiste SL, Wambui J, Meyer-Rath G, Honermann B, Warren M, Bekker LG, Sinxadi P, Collins S, Burry J, Möller K, Clayden P, Owen A, Hill A. Venter WDF, et al. Among authors: clayden p. Lancet HIV. 2024 Oct;11(10):e711-e716. doi: 10.1016/S2352-3018(24)00173-5. Epub 2024 Aug 16. Lancet HIV. 2024. PMID: 39159655 Review.
British HIV Association and Children's HIV Association position statement on infant feeding in the UK 2011.
Taylor GP, Anderson J, Clayden P, Gazzard BG, Fortin J, Kennedy J, Lazarus L, Newell ML, Osoro B, Sellers S, Tookey PA, Tudor-Williams G, Williams A, de Ruiter A; BHIVA/CHIVA Guidelines Writing Group. Taylor GP, et al. Among authors: clayden p. HIV Med. 2011 Aug;12(7):389-93. doi: 10.1111/j.1468-1293.2011.00918.x. Epub 2011 Mar 21. HIV Med. 2011. PMID: 21418503 Free article.
Clinical Outcomes in Children With Human Immunodeficiency Virus Treated for Nonsevere Tuberculosis in the SHINE Trial.
Chabala C, Wobudeya E, van der Zalm MM, Kapasa M, Raichur P, Mboizi R, Palmer M, Kinikar A, Hissar S, Mulenga V, Mave V, Musoke P, Hesseling AC, McIlleron H, Gibb D, Crook A, Turkova A; SHINE Trial Team. Chabala C, et al. Clin Infect Dis. 2024 Jul 19;79(1):70-77. doi: 10.1093/cid/ciae193. Clin Infect Dis. 2024. PMID: 38592950 Free PMC article. Clinical Trial.
Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens.
Sokhela S, Venter WDF, Bosch B, Woods J, McCann K, Akpomiemie G, Chandiwana N, Mashabane N, Tembo A, Simmons B, Lalla-Edward S, Siedner MJ, Sinxadi P, Hermans L, Fairlie L, Vos A, Abrams E, Manne-Goehler JM, Moorhouse M, Clayden P, Norris S, Qavi A, Chersich M, Masenya M, Arulappan N, Hill A. Sokhela S, et al. Among authors: clayden p. Open Forum Infect Dis. 2024 Jan 24;11(3):ofae007. doi: 10.1093/ofid/ofae007. eCollection 2024 Mar. Open Forum Infect Dis. 2024. PMID: 38529213 Free PMC article.
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial.
Turkova A, White E, Kekitiinwa AR, Mumbiro V, Kaudha E, Liberty A, Ahimbisibwe GM, Moloantoa T, Srirompotong U, Mosia NR, Puthanakit T, Kobbe R, Fortuny C, Kataike H, Bbuye D, Na-Rajsima S, Coelho A, Lugemwa A, Bwakura-Dangarembizi MF, Klein N, Mujuru HA, Kityo C, Cotton MF, Ferrand RA, Giaquinto C, Rojo P, Violari A, Gibb DM, Ford D; ODYSSEY trial team. Turkova A, et al. Lancet Child Adolesc Health. 2023 Oct;7(10):718-727. doi: 10.1016/S2352-4642(23)00164-5. Epub 2023 Aug 8. Lancet Child Adolesc Health. 2023. PMID: 37562418 Free PMC article. Clinical Trial.
Inadequate Lopinavir Concentrations With Modified 8-Hourly Lopinavir/Ritonavir 4:1 Dosing During Rifampicin-based Tuberculosis Treatment in Children Living With HIV.
Chabala C, Turkova A, Kapasa M, LeBeau K, Tembo CH, Zimba K, Weisner L, Zyambo K, Choo L, Chungu C, Lungu J, Mulenga V, Crook A, Gibb D, McIlleron H; SHINE trial team. Chabala C, et al. Pediatr Infect Dis J. 2023 Oct 1;42(10):899-904. doi: 10.1097/INF.0000000000004047. Epub 2023 Jul 20. Pediatr Infect Dis J. 2023. PMID: 37506295 Free PMC article.
Response to comments by Taramasso and colleagues on weight gain stopping/switch rules for antiretroviral clinical trials.
Venter F, Sokhela S, Calmy A, Siedner MJ, Khoo S, Clayden P, Mkhondwane L, Bosch B, Chandiwana N, Hill A, Marconi VC, Boffito M, Sekwese K, Ali M, Delaporte E, Pozniak A, Mashabane N, Lalla-Edwards S, Carman M, Collins S. Venter F, et al. Among authors: clayden p. AIDS. 2022 Nov 1;36(13):1900-1901. doi: 10.1097/QAD.0000000000003310. AIDS. 2022. PMID: 36172876 No abstract available.
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial.
Amuge P, Lugemwa A, Wynne B, Mujuru HA, Violari A, Kityo CM, Archary M, Variava E, White E, Turner RM, Shakeshaft C, Ali S, Nathoo KJ, Atwine L, Liberty A, Bbuye D, Kaudha E, Mngqibisa R, Mosala M, Mumbiro V, Nanduudu A, Ankunda R, Maseko L, Kekitiinwa AR, Giaquinto C, Rojo P, Gibb DM, Turkova A, Ford D; ODYSSEY Trial Team. Amuge P, et al. Lancet HIV. 2022 Sep;9(9):e638-e648. doi: 10.1016/S2352-3018(22)00163-1. Lancet HIV. 2022. PMID: 36055295 Free PMC article. Clinical Trial.
72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study.
Malaba TR, Nakatudde I, Kintu K, Colbers A, Chen T, Reynolds H, Read L, Read J, Stemmet LA, Mrubata M, Byrne K, Seden K, Twimukye A, Theunissen H, Hodel EM, Chiong J, Hu NC, Burger D, Wang D, Byamugisha J, Alhassan Y, Bokako S, Waitt C, Taegtmeyer M, Orrell C, Lamorde M, Myer L, Khoo S; DolPHIN-2 Study Group. Malaba TR, et al. Lancet HIV. 2022 Aug;9(8):e534-e543. doi: 10.1016/S2352-3018(22)00173-4. Lancet HIV. 2022. PMID: 35905752 Free article. Clinical Trial.
76 results